2025. Comparative Efficacy of Anastrozole, Letrozole, and Fulvestrant as Endocrine Partners Combined with CDK4/6 Inhibitors in Patients with HR+/HER2– Metastatic Breast Cancer: A Real-World Evidence from the Stavropol Regional Clinical Oncology Center. Voprosy onkologii. 71, 6 (Dec. 2025), OF-2376. DOI:https://doi.org/10.37469/0507-3758-2025-71-6-OF-2376.